{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:17:33Z","timestamp":1778635053072,"version":"3.51.4"},"reference-count":215,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T00:00:00Z","timestamp":1658016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["19AIREA34470007"],"award-info":[{"award-number":["19AIREA34470007"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Alzheimer\u2019s disease remains a prevailing neurodegenerative condition which has an array physical, emotional, and financial consequences to patients and society. In the past decade, there has been a greater degree of investigation on therapeutic small peptides. This group of biomolecules have a profile of fundamentally sound characteristics which make them an intriguing area for drug development. Among these biomolecules, there are four modulatory mechanisms of interest in this review: alpha-, beta-, gamma-secretases, and amylin. These protease-based biomolecules all have a contributory role in the amyloid cascade hypothesis. Moreover, the involvement of various biochemical pathways intertwines these peptides to have shared regulators (i.e., retinoids). Further clinical and translational investigation must occur to gain a greater understanding of its potential application in patient care. The aim of this narrative review is to evaluate the contemporary literature on these protease biomolecule modulators and determine its utility in the treatment of Alzheimer\u2019s disease.<\/jats:p>","DOI":"10.3390\/biom12070996","type":"journal-article","created":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T21:00:28Z","timestamp":1658091628000},"page":"996","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Amylin and Secretases in the Pathology and Treatment of Alzheimer\u2019s Disease"],"prefix":"10.3390","volume":"12","author":[{"given":"Som","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, School of Medicine, University of Missouri, Kansas City, MO 64108, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, School of Medicine, University of Missouri, Kansas City, MO 64108, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Sivils","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, School of Medicine, University of Missouri, Kansas City, MO 64108, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3800-1872","authenticated-orcid":false,"given":"Victoria","family":"Cegielski","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, School of Medicine, University of Missouri, Kansas City, MO 64108, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6781-0468","authenticated-orcid":false,"given":"Xiang-Ping","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, School of Medicine, University of Missouri, Kansas City, MO 64108, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,17]]},"reference":[{"key":"ref_1","first-page":"149","article-title":"Epidemiology of Alzheimer\u2019s disease: Latest trends","volume":"70","author":"Dumurgier","year":"2020","journal-title":"Rev. Prat."},{"key":"ref_2","first-page":"313","article-title":"The Epidemiology of Alzheimer\u2019s Disease Modifiable Risk Factors and Prevention","volume":"8","author":"Zhang","year":"2021","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jalz.2019.04.001","article-title":"Duration of Preclinical, Prodromal, and Dementia Stages of Alzheimer\u2019s Disease in Relation to Age, Sex, and APOE Genotype","volume":"15","author":"Vermunt","year":"2019","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","article-title":"Preclinical Alzheimer\u2019s Disease: Definition, Natural History, and Diagnostic Criteria","volume":"12","author":"Dubois","year":"2016","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of Cerebral Amyloid Pathology in Persons without Dementia: A Meta-Analysis","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a Biological Definition of Alzheimer\u2019s Disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1152\/physrev.00015.2020","article-title":"The Complexity of Alzheimer\u2019s Disease: An Evolving Puzzle","volume":"101","author":"Ferrari","year":"2021","journal-title":"Physiol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0140-6736(10)61349-9","article-title":"Alzheimer\u2019s Disease","volume":"377","author":"Ballard","year":"2011","journal-title":"Lancet Lond. Engl."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrd3505","article-title":"The Amyloid Cascade Hypothesis for Alzheimer\u2019s Disease: An Appraisal for the Development of Therapeutics","volume":"10","author":"Karran","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.bbamem.2018.02.022","article-title":"Amyloid Growth and Membrane Damage: Current Themes and Emerging Perspectives from Theory and Experiments on A\u03b2 and HIAPP","volume":"1860","author":"Sciacca","year":"2018","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","article-title":"Amyloid Deposition as the Central Event in the Aetiology of Alzheimer\u2019s Disease","volume":"12","author":"Hardy","year":"1991","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"172415","DOI":"10.1016\/j.ejphar.2019.172415","article-title":"Trafficking and Proteolytic Processing of Amyloid Precursor Protein and Secretases in Alzheimer\u2019s Disease Development: An up-to-Date Review","volume":"856","author":"Yuksel","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/emmm.201100195","article-title":"\u03b2- but Not \u03b3-Secretase Proteolysis of APP Causes Synaptic and Memory Deficits in a Mouse Model of Dementia","volume":"4","author":"Tamayev","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3233\/JAD-180802","article-title":"Understanding the Amyloid Hypothesis in Alzheimer\u2019s Disease","volume":"68","author":"Paroni","year":"2019","journal-title":"J. Alzheimers Dis. JAD"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"eaao4827","DOI":"10.1126\/science.aao4827","article-title":"Secreted Amyloid-\u03b2 Precursor Protein Functions as a GABABR1a Ligand to Modulate Synaptic Transmission","volume":"363","author":"Rice","year":"2019","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with Amyloid-Beta Attenuates Alzheimer-Disease-like Pathology in the PDAPP Mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/alz.12124","article-title":"An Agnostic Reevaluation of the Amyloid Cascade Hypothesis of Alzheimer\u2019s Disease Pathogenesis: The Role of APP Homeostasis","volume":"16","author":"Caselli","year":"2020","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jalz.2019.09.075","article-title":"The Path Forward in Alzheimer\u2019s Disease Therapeutics: Reevaluating the Amyloid Cascade Hypothesis","volume":"16","author":"Tolar","year":"2020","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/head.13084","article-title":"Overview of Neuropeptides: Awakening the Senses?","volume":"57","author":"Russo","year":"2017","journal-title":"Headache"},{"key":"ref_20","unstructured":"Purves, D., Augustine, G.J., Fitzpatrick, D., Katz, L.C., LaMantia, A.-S., McNamara, J.O., and Williams, S.M. (2001). Peptide Neurotransmitters. Neuroscience, Sinauer Associates. [2nd ed.]."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2174\/1389203722666210920151810","article-title":"Rachana, null Peptide Based Therapy for Neurological Disorders","volume":"22","author":"Yadav","year":"2021","journal-title":"Curr. Protein Pept. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1042\/BCJ20200290","article-title":"Rationally Designed Peptide-Based Inhibitor of A\u03b242 Fibril Formation and Toxicity: A Potential Therapeutic Strategy for Alzheimer\u2019s Disease","volume":"477","author":"Horsley","year":"2020","journal-title":"Biochem. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13195-022-00959-z","article-title":"A Novel D-Amino Acid Peptide with Therapeutic Potential (ISAD1) Inhibits Aggregation of Neurotoxic Disease-Relevant Mutant Tau and Prevents Tau Toxicity in Vitro","volume":"14","author":"Aillaud","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3233\/JAD-141704","article-title":"Potassium Channel Kv1.3 Is Highly Expressed by Microglia in Human Alzheimer\u2019s Disease","volume":"44","author":"Rangaraju","year":"2015","journal-title":"J. Alzheimers Dis. JAD"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/brain\/awx346","article-title":"Kv1.3 Inhibition as a Potential Microglia-Targeted Therapy for Alzheimer\u2019s Disease: Preclinical Proof of Concept","volume":"141","author":"Maezawa","year":"2018","journal-title":"Brain J. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrneurol.2009.218","article-title":"The Secretases: Enzymes with Therapeutic Potential in Alzheimer Disease","volume":"6","author":"Vassar","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"FSO11","DOI":"10.4155\/fso.15.9","article-title":"The Role and Therapeutic Targeting of \u03b1-, \u03b2- and \u03b3-Secretase in Alzheimer\u2019s Disease","volume":"1","author":"MacLeod","year":"2015","journal-title":"Future Sci. OA"},{"key":"ref_28","unstructured":"Ishiura, S., Asai, M., Hattori, C., Hotoda, N., Szabo, B., Sasagawa, N., and Tanuma, S. (2013). APP \u03b1-Secretase, a Novel Target for Alzheimer Drug Therapy, Landes Bioscience."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2015.10.003","article-title":"The Alpha Secretase ADAM10: A Metalloprotease with Multiple Functions in the Brain","volume":"135","author":"Saftig","year":"2015","journal-title":"Prog. Neurobiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41380-018-0091-8","article-title":"A Rare Loss-of-Function Variant of ADAM17 Is Associated with Late-Onset Familial Alzheimer Disease","volume":"25","author":"Hartl","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Peron, R., Vatanabe, I.P., Manzine, P.R., Camins, A., and Cominetti, M.R. (2018). Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer\u2019s Disease Treatment. Pharm. Basel Switz., 11.","DOI":"10.3390\/ph11010012"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"991","DOI":"10.3233\/JAD-151098","article-title":"Maintenance of Cognitive Performance and Mood for Individuals with Alzheimer\u2019s Disease Following Consumption of a Nutraceutical Formulation: A One-Year, Open-Label Study","volume":"51","author":"Remington","year":"2016","journal-title":"J. Alzheimers Dis. JAD"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3233\/ADR-190104","article-title":"Gemfibrozil, a Lipid-Lowering Drug, Lowers Amyloid Plaque Pathology and Enhances Memory in a Mouse Model of Alzheimer\u2019s Disease via Peroxisome Proliferator-Activated Receptor \u03b1","volume":"3","author":"Chandra","year":"2019","journal-title":"J. Alzheimers Dis. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41597-021-01054-y","article-title":"Systematic Phenotyping and Characterization of the 5xFAD Mouse Model of Alzheimer\u2019s Disease","volume":"8","author":"Forner","year":"2021","journal-title":"Sci. Data"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Jeong, Y.J., Son, Y., Park, H.-J., Oh, S.J., Choi, J.Y., Ko, Y.-G., and Lee, H.-J. (2021). Therapeutic Effects of Aripiprazole in the 5xFAD Alzheimer\u2019s Disease Mouse Model. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179374"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Oblak, A.L., Lin, P.B., Kotredes, K.P., Pandey, R.S., Garceau, D., Williams, H.M., Uyar, A., O\u2019Rourke, R., O\u2019Rourke, S., and Ingraham, C. (2021). Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD Study. Front. Aging Neurosci., 13.","DOI":"10.3389\/fnagi.2021.713726"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"S\u00e1ez-Orellana, F., Octave, J.-N., and Pierrot, N. (2020). Alzheimer\u2019s Disease, a Lipid Story: Involvement of Peroxisome Proliferator-Activated Receptor \u03b1. Cells, 9.","DOI":"10.3390\/cells9051215"},{"key":"ref_38","unstructured":"(2022, May 19). Metabolic and Cerebrovascular Effects of Gemfibrozil Treatment: A Randomized, Placebo-controlled, Double-blind, Phase II Clinical Trial for Dementia Prevention\u2014Jicha\u20142021\u2014Alzheimer\u2019s & Dementia\u2014Wiley Online Library. Available online: https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/abs\/10.1002\/alz.055777."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejphar.2009.03.047","article-title":"Involvement of Protein Trafficking in Deprenyl-Induced Alpha-Secretase Activity Regulation in PC12 Cells","volume":"610","author":"Yang","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/j.1471-4159.2004.02521.x","article-title":"Atorvastatin-Induced Activation of Alzheimer\u2019s Alpha Secretase Is Resistant to Standard Inhibitors of Protein Phosphorylation-Regulated Ectodomain Shedding","volume":"90","author":"Parvathy","year":"2004","journal-title":"J. Neurochem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12974-018-1255-9","article-title":"Levels of ADAM10 Are Reduced in Alzheimer\u2019s Disease CSF","volume":"15","author":"Gobom","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nn.2794","article-title":"SFRPs Act as Negative Modulators of ADAM10 to Regulate Retinal Neurogenesis","volume":"14","author":"Esteve","year":"2011","journal-title":"Nat. Neurosci."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Tang, B.L. (2020). Enhancing \u03b1-Secretase Processing for Alzheimer\u2019s Disease-A View on SFRP1. Brain Sci., 10.","DOI":"10.3390\/brainsci10020122"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/s41593-019-0432-1","article-title":"Elevated Levels of Secreted-Frizzled-Related-Protein 1 Contribute to Alzheimer\u2019s Disease Pathogenesis","volume":"22","author":"Esteve","year":"2019","journal-title":"Nat. Neurosci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1128\/MCB.02185-07","article-title":"Crystal Structure of an Active Form of BACE1, an Enzyme Responsible for Amyloid \u03b2 Protein Production","volume":"28","author":"Shimizu","year":"2008","journal-title":"Mol. Cell. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1073\/pnas.97.4.1456","article-title":"Human Aspartic Protease Memapsin 2 Cleaves the Beta-Secretase Site of Beta-Amyloid Precursor Protein","volume":"97","author":"Lin","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1107\/S0907444911047251","article-title":"Flexibility of the Flap in the Active Site of BACE1 as Revealed by Crystal Structures and Molecular Dynamics Simulations","volume":"68","author":"Xu","year":"2012","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature11283","article-title":"A Mutation in APP Protects against Alzheimer\u2019s Disease and Age-Related Cognitive Decline","volume":"488","author":"Jonsson","year":"2012","journal-title":"Nature"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0896-6273(03)00810-9","article-title":"BACE1 Deficiency Rescues Memory Deficits and Cholinergic Dysfunction in a Mouse Model of Alzheimer\u2019s Disease","volume":"41","author":"Ohno","year":"2004","journal-title":"Neuron"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1038\/emboj.2013.146","article-title":"Bace1 and Neuregulin-1 Cooperate to Control Formation and Maintenance of Muscle Spindles","volume":"32","author":"Cheret","year":"2013","journal-title":"EMBO J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e201800026","DOI":"10.26508\/lsa.201800026","article-title":"BACE2 Distribution in Major Brain Cell Types and Identification of Novel Substrates","volume":"1","author":"Voytyuk","year":"2018","journal-title":"Life Sci. Alliance"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/cmdc.201800725","article-title":"Highly Selective and Potent Human \u03b2-Secretase 2 (BACE2) Inhibitors against Type 2 Diabetes: Design, Synthesis, X-Ray Structure and Structure-Activity Relationship Studies","volume":"14","author":"Ghosh","year":"2019","journal-title":"ChemMedChem"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"123431","DOI":"10.1172\/jci.insight.123431","article-title":"BACE2, a Conditional \u03b2-Secretase, Contributes to Alzheimer\u2019s Disease Pathogenesis","volume":"4","author":"Wang","year":"2019","journal-title":"JCI Insight"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"30797","DOI":"10.1074\/jbc.M505249200","article-title":"Phenotypic and Biochemical Analyses of BACE1- and BACE2-Deficient Mice","volume":"280","author":"Dominguez","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"9640","DOI":"10.1038\/s41598-019-45896-4","article-title":"Common BACE2 Polymorphisms Are Associated with Altered Risk for Alzheimer\u2019s Disease and CSF Amyloid Biomarkers in APOE \u03954 Non-Carriers","volume":"9","author":"Huentelman","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_56","first-page":"1369","article-title":"BACE2, as a Novel APP Theta-Secretase, Is Not Responsible for the Pathogenesis of Alzheimer\u2019s Disease in Down Syndrome","volume":"20","author":"Sun","year":"2006","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jshs.2016.10.004","article-title":"BACE1 Inhibition as a Therapeutic Strategy for Alzheimer\u2019s Disease","volume":"5","author":"Vassar","year":"2016","journal-title":"J. Sport Health Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40263-019-00613-7","article-title":"A Close Look at BACE1 Inhibitors for Alzheimer\u2019s Disease Treatment","volume":"33","author":"Das","year":"2019","journal-title":"CNS Drugs"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3389\/fnagi.2014.00165","article-title":"\u03b2-Secretase Inhibitor; a Promising Novel Therapeutic Drug in Alzheimer\u2019s Disease","volume":"6","author":"Menting","year":"2014","journal-title":"Front. Aging Neurosci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1471-4159.2011.07476.x","article-title":"Developing \u03b2-Secretase Inhibitors for Treatment of Alzheimer\u2019s Disease","volume":"120","author":"Ghosh","year":"2012","journal-title":"J. Neurochem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1021\/ja000300g","article-title":"Design of Potent Inhibitors for Human Brain Memapsin 2 (\u03b2-Secretase)","volume":"122","author":"Ghosh","year":"2000","journal-title":"J. Am. Chem. Soc."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1016\/j.bmcl.2006.05.046","article-title":"Beta-Secretase Inhibitors: Modification at the P4 Position and Improvement of Inhibitory Activity in Cultured Cells","volume":"16","author":"Hamada","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_63","first-page":"618","article-title":"Inhibition of BACE1 for Therapeutic Use in Alzheimer\u2019s Disease","volume":"3","author":"Luo","year":"2010","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"363ra150","DOI":"10.1126\/scitranslmed.aad9704","article-title":"The BACE1 Inhibitor Verubecestat (MK-8931) Reduces CNS \u03b2-Amyloid in Animal Models and in Alzheimer\u2019s Disease Patients","volume":"8","author":"Kennedy","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Maia, M.A., and Sousa, E. (2019). BACE-1 and \u03b3-Secretase as Therapeutic Targets for Alzheimer\u2019s Disease. Pharmaceuticals, 12.","DOI":"10.3390\/ph12010041"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13195-019-0520-1","article-title":"Further Analyses of the Safety of Verubecestat in the Phase 3 EPOCH Trial of Mild-to-Moderate Alzheimer\u2019s Disease","volume":"11","author":"Egan","year":"2019","journal-title":"Alzheimers Res. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1523\/JNEUROSCI.4129-14.2015","article-title":"The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central A\u03b2 Pharmacodynamic Responses in Mice, Dogs, and Humans","volume":"35","author":"May","year":"2015","journal-title":"J. Neurosci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13195-020-00635-0","article-title":"Partial Reduction of Amyloid \u03b2 Production by \u03b2-Secretase Inhibitors Does Not Decrease Synaptic Transmission","volume":"12","author":"Satir","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1158\/2159-8290.CD-21-1006","article-title":"Melanoma-Secreted Amyloid Beta Suppresses Neuroinflammation and Promotes Brain Metastasis","volume":"12","author":"Kleffman","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.bbamem.2013.06.005","article-title":"\u03b3-Secretase Inhibitors and Modulators","volume":"1828","author":"Golde","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1755-5949.2010.00164.x","article-title":"REVIEW: \u0393-Secretase Inhibitors for the Treatment of Alzheimer\u2019s Disease: The Current State","volume":"16","author":"Panza","year":"2010","journal-title":"CNS Neurosci. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.nurt.2008.05.010","article-title":"Inhibition and Modulation of \u03b3-Secretase for Alzheimer\u2019s Disease","volume":"5","author":"Wolfe","year":"2008","journal-title":"Neurotherapeutics"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/00019442-200403000-00006","article-title":"Clinical, Pathological, and Biochemical Spectrum of Alzheimer Disease Associated with PS-1 Mutations","volume":"12","author":"Berezovska","year":"2004","journal-title":"Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1471-4159.2005.03578.x","article-title":"Presenilin Clinical Mutations Can Affect Gamma-Secretase Activity by Different Mechanisms","volume":"96","author":"Bentahir","year":"2006","journal-title":"J. Neurochem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nature01506","article-title":"The Role of Presenilin Cofactors in the \u03b3-Secretase Complex","volume":"422","author":"Takasugi","year":"2003","journal-title":"Nature"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Liu, X., Liu, Y., and Ji, S. (2021). Secretases Related to Amyloid Precursor Protein Processing. Membranes, 11.","DOI":"10.3390\/membranes11120983"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.pneurobio.2008.05.002","article-title":"The Amyloid Precursor Protein Intracellular Domain (AICD) as Modulator of Gene Expression, Apoptosis, and Cytoskeletal Dynamics-Relevance for Alzheimer\u2019s Disease","volume":"85","author":"Meyer","year":"2008","journal-title":"Prog. Neurobiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1600-0854.2006.00396.x","article-title":"Amyloid Precursor Protein and Notch Intracellular Domains Are Generated after Transport of Their Precursors to the Cell Surface","volume":"7","author":"Kaether","year":"2006","journal-title":"Traffic Cph. Den."},{"key":"ref_79","first-page":"635","article-title":"A CBP Binding Transcriptional Repressor Produced by the PS1\/Epsilon-Cleavage of N-Cadherin Is Inhibited by PS1 FAD Mutations","volume":"114","author":"Marambaud","year":"2003","journal-title":"Cell"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/19083","article-title":"A Presenilin-1-Dependent Gamma-Secretase-like Protease Mediates Release of Notch Intracellular Domain","volume":"398","author":"Annaert","year":"1999","journal-title":"Nature"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1126\/science.1065412","article-title":"Gamma -Secretase Cleavage and Nuclear Localization of ErbB-4 Receptor Tyrosine Kinase","volume":"294","author":"Ni","year":"2001","journal-title":"Science"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A Phase 3 Trial of Semagacestat for Treatment of Alzheimer\u2019s Disease","volume":"369","author":"Doody","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"10405","DOI":"10.1523\/JNEUROSCI.2288-09.2009","article-title":"\u03b3-Secretase Inhibition Reduces Spine Density In Vivo via an Amyloid Precursor Protein-Dependent Pathway","volume":"29","author":"Bittner","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.21623","article-title":"A Gamma-Secretase Inhibitor Decreases Amyloid-Beta Production in the Central Nervous System","volume":"66","author":"Bateman","year":"2009","journal-title":"Ann. Neurol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.1021\/bi301137h","article-title":"BMS-708,163 Targets Presenilin and Lacks Notch-Sparing Activity","volume":"51","author":"Crump","year":"2012","journal-title":"Biochemistry"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"950","DOI":"10.15252\/emmm.201607265","article-title":"\u03b3-Secretase Inhibitors in Cancer Clinical Trials Are Pharmacologically and Functionally Distinct","volume":"9","author":"Ran","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s12276-022-00754-8","article-title":"\u03b3-Secretase in Alzheimer\u2019s Disease","volume":"54","author":"Hur","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1152\/physrev.00042.2009","article-title":"Islet Amyloid Polypeptide, Islet Amyloid, and Diabetes Mellitus","volume":"91","author":"Westermark","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_89","first-page":"245","article-title":"Impaired Glucose Tolerance Is Associated with Increased Islet Amyloid Polypeptide (IAPP) Immunoreactivity in Pancreatic Beta Cells","volume":"135","author":"Johnson","year":"1989","journal-title":"Am. J. Pathol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/0006-291X(90)90359-U","article-title":"Canine IAPP CDNA Sequence Provides Important Clues Regarding Diabetogenesis and Amyloidogenesis in Type 2 Diabetes","volume":"169","author":"Jordan","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuropharm.2017.12.016","article-title":"Amylin in Alzheimer\u2019s Disease: Pathological Peptide or Potential Treatment?","volume":"136","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.molmed.2017.06.003","article-title":"Amylin Receptor: A Potential Therapeutic Target for Alzheimer\u2019s Disease","volume":"23","author":"Fu","year":"2017","journal-title":"Trends Mol. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s12035-016-9684-x","article-title":"Pramlintide Antagonizes Beta Amyloid (A\u03b2)- and Human Amylin-Induced Depression of Hippocampal Long-Term Potentiation","volume":"54","author":"Kimura","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/mp.2014.17","article-title":"Intraperitoneal Injection of the Pancreatic Peptide Amylin Potently Reduces Behavioral Impairment and Brain Amyloid Pathology in Murine Models of Alzheimer\u2019s Disease","volume":"20","author":"Zhu","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3233\/JAD-180433","article-title":"Neuroprotective Effects of Amylin Analogues on Alzheimer\u2019s Disease Pathogenesis and Cognition","volume":"66","author":"Grizzanti","year":"2018","journal-title":"J. Alzheimers Dis. JAD"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1080\/13813455.2018.1534244","article-title":"Effect of Amylin on Memory and Central Insulin Resistance in a Rat Model of Alzheimer\u2019s Disease","volume":"126","author":"Nassar","year":"2020","journal-title":"Arch. Physiol. Biochem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"15333175211012868","DOI":"10.1177\/15333175211012867","article-title":"Oral Amylin Treatment Reduces the Pathological Cascade of Alzheimer\u2019s Disease in a Mouse Model","volume":"36","author":"Na","year":"2021","journal-title":"Am. J. Alzheimers Dis. Other Demen."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"18820","DOI":"10.1074\/jbc.M111.331181","article-title":"Amyloid \u03b2 (A\u03b2) Peptide Directly Activates Amylin-3 Receptor Subtype by Triggering Multiple Intracellular Signaling Pathways","volume":"287","author":"Fu","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fnmol.2015.00078","article-title":"Role of Immediate-Early Genes in Synaptic Plasticity and Neuronal Ensembles Underlying the Memory Trace","volume":"8","author":"Minatohara","year":"2016","journal-title":"Front. Mol. Neurosci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3389\/fncel.2017.00184","article-title":"Activation of the CREB\/c-Fos Pathway during Long-Term Synaptic Plasticity in the Cerebellum Granular Layer","volume":"11","author":"Gandolfi","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.neuropharm.2017.03.030","article-title":"Amylin Receptor Ligands Reduce the Pathological Cascade of Alzheimer\u2019s Disease","volume":"119","author":"Zhu","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.crbiot.2020.10.002","article-title":"Insights from Nature: A Review of Natural Compounds That Target Protein Misfolding in Vivo","volume":"2","author":"Terry","year":"2020","journal-title":"Curr. Res. Biotechnol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"(2021). 2021 Alzheimer\u2019s Disease Facts and Figures. Alzheimers Dement. J. Alzheimers Assoc., 17, 327\u2013406.","DOI":"10.1002\/alz.12328"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fnins.2019.00038","article-title":"Innovative Therapy for Alzheimer\u2019s Disease-With Focus on Biodelivery of NGF","volume":"13","author":"Mitra","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1080\/13696998.2021.1927747","article-title":"Modelling the Value of Innovative Treatments for Alzheimer\u2019s Disease in the United States","volume":"24","author":"Makin","year":"2021","journal-title":"J. Med. Econ."},{"key":"ref_106","first-page":"107","article-title":"The Adoption of Pharmaceutical Innovation and Its Impact on the Treatment Costs for Alzheimer\u2019s Disease in Taiwan","volume":"17","author":"Lo","year":"2014","journal-title":"J. Ment. Health Policy Econ."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jalz.2018.02.007","article-title":"Accelerating Alzheimer\u2019s Disease Drug Innovations from the Research Pipeline to Patients","volume":"14","author":"Goldman","year":"2018","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2174\/1567205017666201203121907","article-title":"How Much Value Would a Treatment for Alzheimer\u2019s Disease Offer? Cost-Effectiveness Thresholds for Pricing a Disease-Modifying Therapy","volume":"17","author":"Jun","year":"2020","journal-title":"Curr. Alzheimer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13195-016-0207-9","article-title":"Drug Development in Alzheimer\u2019s Disease: The Path to 2025","volume":"8","author":"Cummings","year":"2016","journal-title":"Alzheimers Res. Ther."},{"key":"ref_110","unstructured":"Jicha, G. (2022, July 04). Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease, Available online: clinicaltrials.gov."},{"key":"ref_111","unstructured":"(2022, July 04). Wyeth is now a wholly owned subsidiary of Pfizer an Open-Label, Nonrandomized Study To Evaluate The Potential Pharmacokinetic Interaction Between SAM-531 and Gemfibrozil, A Cytochrome P-450 2C8 Inhibitor, When Coadministered Orally To Healthy Young Adult Subjects, Available online: clinicaltrials.gov."},{"key":"ref_112","unstructured":"Lieb, K. (2022, July 11). Changes of Cerebral Spinal Fluid APPS\u03b1 Levels Under Oral Therapy With Acitretin 30 Mg Daily in Patients With Mild to Moderate Alzheimer\u2019s Disease: A Multicenter Prospective Randomised Placebo-Controlled Parallel-Group Study, Available online: clinicaltrials.gov."},{"key":"ref_113","unstructured":"(2022, July 11). Aphios Safety, Tolerability and Efficacy Assessment of Intranasal Nanoparticles of APH-1105, A Novel Alpha Secretase Modulator For Mild to Moderate Cognitive Impairment Due to Alzheimer\u2019s Disease(AD), Available online: clinicaltrials.gov."},{"key":"ref_114","unstructured":"Paul, F. (2022, July 11). Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer\u00b4s Disease, Available online: clinicaltrials.gov."},{"key":"ref_115","unstructured":"(2022, July 11). AstraZeneca A Single-Center, Randomized, Double-Blinded, Placebo-Controlled, 4-Way Cross-over Study to Assess the Effect of a Single Oral Dose of AZD3293 Administration on QTc Interval Compared to Placebo, Using Open-Label AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Subjects, Available online: clinicaltrials.gov."},{"key":"ref_116","unstructured":"(2022, July 11). Eli Lilly and Company Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer\u2019s Disease or Mild Alzheimer\u2019s Disease, Available online: clinicaltrials.gov."},{"key":"ref_117","unstructured":"Janssen Pharmaceutical, K.K. (2022, July 11). A Double-Blind, Placebo-Controlled, Randomized, 4-Week, Multiple-Dose, Proof of Mechanism (POM) Study in Japanese Subjects Asymptomatic at Risk for Alzheimer Dementia (ARAD) Investigating the Effects of JNJ-54861911 on A-Beta Processing in Cerebrospinal Fluid (CSF) and Plasma, Available online: clinicaltrials.gov."},{"key":"ref_118","unstructured":"(2022, July 11). Janssen Research & Development, LLC A Randomized, Two-Period, Double-Blind Placebo-Controlled and Open-Label, Multicenter Extension Study to Determine the Long-Term Safety and Tolerability of JNJ-54861911 in Subjects in the Early Alzheimer\u2019s Disease Spectrum, Available online: clinicaltrials.gov."},{"key":"ref_119","unstructured":"(2022, July 11). Novartis Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of CNP520 in Healthy Elderly Subjects, Available online: clinicaltrials.gov."},{"key":"ref_120","unstructured":"(2022, July 11). Merck Sharp & Dohme LLC A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects With Amnestic Mild Cognitive Impairment Due to Alzheimer\u2019s Disease (Prodromal AD), Available online: clinicaltrials.gov."},{"key":"ref_121","unstructured":"(2022, July 11). Eli Lilly and Company Effect of \u03b3-Secretase Inhibition on the Progression of Alzheimer\u2019s Disease: LY450139 Versus Placebo, Available online: clinicaltrials.gov."},{"key":"ref_122","unstructured":"(2022, July 11). Eli Lilly and Company Open-Label Extension for Alzheimer\u2019s Disease Patients Who Complete One of Two Semagacestat Phase 3 Double-Blind Studies (H6L-MC-LFAN or H6L-MC-LFBC), Available online: clinicaltrials.gov."},{"key":"ref_123","unstructured":"(2022, July 11). Bristol-Myers Squibb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients With Prodromal Alzheimer\u2019s Disease, Available online: clinicaltrials.gov."},{"key":"ref_124","unstructured":"(2022, July 11). Wyeth is now a wholly owned subsidiary of Pfizer Ascending Single-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-136 Administered Orally to Healthy Japanese Male Subjects and Healthy Japanese Elderly Male Subjects, Available online: clinicaltrials.gov."},{"key":"ref_125","unstructured":"(2022, July 11). NeuroGenetic Pharmaceuticals Inc A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally-Administered NGP 555 in Healthy Young Volunteers, Available online: clinicaltrials.gov."},{"key":"ref_126","unstructured":"(2022, July 11). National Institute on Aging (NIA) A Pilot Study of Exendin-4 in Alzheimer s Disease, Available online: clinicaltrials.gov."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Apostolopoulos, V., Bojarska, J., Chai, T.-T., Elnagdy, S., Kaczmarek, K., Matsoukas, J., New, R., Parang, K., Lopez, O.P., and Parhiz, H. (2021). A Global Review on Short Peptides: Frontiers and Perspectives. Mol. Basel Switz., 26.","DOI":"10.3390\/molecules26020430"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1080\/14712598.2019.1652592","article-title":"Selected Application of Peptide Molecules as Pharmaceutical Agents and in Cosmeceuticals","volume":"19","author":"Negahdaripour","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/gen.33.13.18","article-title":"Reducing the Cost of Peptide Synthesis","volume":"33","author":"Glaser","year":"2013","journal-title":"Genet. Eng. Biotechnol. News"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., and Fu, C. (2022). Therapeutic Peptides: Current Applications and Future Directions. Signal Transduct. Target. Ther., 7.","DOI":"10.1038\/s41392-022-00904-4"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fnins.2018.00025","article-title":"Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer\u2019s Disease","volume":"12","author":"Kametani","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fnagi.2018.00118","article-title":"The Physiological Roles of Amyloid-\u03b2 Peptide Hint at New Ways to Treat Alzheimer\u2019s Disease","volume":"10","author":"Brothers","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"13042","DOI":"10.1073\/pnas.2135111100","article-title":"Interaction between the Alzheimer\u2019s Survival Peptide Humanin and Insulin-like Growth Factor-Binding Protein 3 Regulates Cell Survival and Apoptosis","volume":"100","author":"Ikonen","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/157488909787002609","article-title":"Humanin; a Defender against Alzheimer\u2019s Disease?","volume":"4","author":"Matsuoka","year":"2009","journal-title":"Recent Patents CNS Drug Discov."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"130024","DOI":"10.1016\/j.bbagen.2021.130024","article-title":"Humanin and Alzheimer\u2019s Disease: The Beginning of a New Field","volume":"1866","author":"Niikura","year":"2022","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"14212","DOI":"10.1038\/s41598-018-32616-7","article-title":"Humanin Prevents Age-Related Cognitive Decline in Mice and Is Associated with Improved Cognitive Age in Humans","volume":"8","author":"Yen","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_137","first-page":"606","article-title":"The Molecular Structure and Role of Humanin in Neural and Skeletal Diseases, and in Tissue Regeneration","volume":"10","author":"Zhu","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41392-019-0063-8","article-title":"History and Progress of Hypotheses and Clinical Trials for Alzheimer\u2019s Disease","volume":"4","author":"Liu","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"140443","DOI":"10.1016\/j.bbapap.2020.140443","article-title":"The Aging Lysosome: An Essential Catalyst for Late-Onset Neurodegenerative Diseases","volume":"1868","author":"Nixon","year":"2020","journal-title":"Biochim. Biophys. Acta Proteins Proteomics"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Kim, N., and Lee, H.J. (2021). Redox-Active Metal Ions and Amyloid-Degrading Enzymes in Alzheimer\u2019s Disease. Int. J. Mol. Sci., 22.","DOI":"10.37247\/PAMOL2ED.3.2021.2"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40035-020-00189-z","article-title":"Current Understanding of Metal Ions in the Pathogenesis of Alzheimer\u2019s Disease","volume":"9","author":"Wang","year":"2020","journal-title":"Transl. Neurodegener."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Bukar Maina, M., Al-Hilaly, Y.K., and Serpell, L.C. (2016). Nuclear Tau and Its Potential Role in Alzheimer\u2019s Disease. Biomolecules, 6.","DOI":"10.3390\/biom6010009"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"12845","DOI":"10.1074\/jbc.M808759200","article-title":"Propagation of Tau Misfolding from the Outside to the Inside of a Cell","volume":"284","author":"Frost","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Harada, R., Okamura, N., Furumoto, S., Tago, T., Yanai, K., Arai, H., and Kudo, Y. (2016). Characteristics of Tau and Its Ligands in PET Imaging. Biomolecules, 6.","DOI":"10.3390\/biom6010007"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Hasegawa, M. (2016). Molecular Mechanisms in the Pathogenesis of Alzheimer\u2019s Disease and Tauopathies-Prion-Like Seeded Aggregation and Phosphorylation. Biomolecules, 6.","DOI":"10.3390\/biom6020024"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Medina, M., Hern\u00e1ndez, F., and Avila, J. (2016). New Features about Tau Function and Dysfunction. Biomolecules, 6.","DOI":"10.3390\/biom6020021"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"\u0160imi\u0107, G., Babi\u0107 Leko, M., Wray, S., Harrington, C., Delalle, I., Jovanov-Milo\u0161evi\u0107, N., Ba\u017eadona, D., Bu\u00e9e, L., De Silva, R., and Di Giovanni, G. (2016). Tau Protein Hyperphosphorylation and Aggregation in Alzheimer\u2019s Disease and Other Tauopathies, and Possible Neuroprotective Strategies. Biomolecules, 6.","DOI":"10.3390\/biom6010006"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"112915","DOI":"10.1016\/j.ejmech.2020.112915","article-title":"Small Molecule Therapeutics for Tauopathy in Alzheimer\u2019s Disease: Walking on the Path of Most Resistance","volume":"209","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7861\/clinmedicine.16-3-247","article-title":"Drug Treatments in Alzheimer\u2019s Disease","volume":"16","author":"Briggs","year":"2016","journal-title":"Clin. Med. Lond. Engl."},{"key":"ref_150","unstructured":"(2022, July 04). Eli Lilly and Company Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer\u2019s Disease, Available online: clinicaltrials.gov."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"173554","DOI":"10.1016\/j.ejphar.2020.173554","article-title":"Alzheimer\u2019s Disease: Recent Treatment Strategies","volume":"887","author":"Vaz","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1179573520907397","DOI":"10.1177\/1179573520907397","article-title":"Current and Future Treatments in Alzheimer Disease: An Update","volume":"12","author":"Yiannopoulou","year":"2020","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.2165\/11595870-000000000-00000","article-title":"Current and Emerging Drug Treatment Options for Alzheimer\u2019s Disease: A Systematic Review","volume":"71","author":"Herrmann","year":"2011","journal-title":"Drugs"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/pds.3303","article-title":"Use of Drug Treatments for Alzheimer\u2019s Disease in France: A Study on a National Level Based on the National Alzheimer\u2019s Data Bank (Banque Nationale Alzheimer)","volume":"21","author":"Tifratene","year":"2012","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.amjmed.2006.08.036","article-title":"Effective Pharmacologic Management of Alzheimer\u2019s Disease","volume":"120","author":"Farlow","year":"2007","journal-title":"Am. J. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-0039-1678581","article-title":"Current and Future Treatments in Alzheimer\u2019s Disease","volume":"39","author":"Atri","year":"2019","journal-title":"Semin. Neurol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00002512-199914050-00004","article-title":"Recent Developments in the Drug Treatment of Alzheimer\u2019s Disease","volume":"14","author":"Sramek","year":"1999","journal-title":"Drugs Aging"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13578-021-00738-7","article-title":"Turning the Tide on Alzheimer\u2019s Disease: Modulation of \u03b3-Secretase","volume":"12","author":"Luo","year":"2022","journal-title":"Cell Biosci."},{"key":"ref_159","first-page":"1126","article-title":"Alpha, Beta-and Gamma-Secretases in Alzheimer\u2019s Disease","volume":"4","author":"Epis","year":"2012","journal-title":"Front. Biosci.-Sch."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3233\/JAD-160275","article-title":"Pharmacological Agents Targeting \u03b3-Secretase Increase Risk of Cancer and Cognitive Decline in Alzheimer\u2019s Disease Patients: A Systematic Review and Meta-Analysis","volume":"53","author":"Penninkilampi","year":"2016","journal-title":"J. Alzheimers Dis. JAD"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ejmech.2018.02.035","article-title":"Secretase Inhibitors for the Treatment of Alzheimer\u2019s Disease: Long Road Ahead","volume":"148","author":"Kumar","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Mouchlis, V.D., Melagraki, G., Zacharia, L.C., and Afantitis, A. (2020). Computer-Aided Drug Design of \u03b2-Secretase, \u03b3-Secretase and Anti-Tau Inhibitors for the Discovery of Novel Alzheimer\u2019s Therapeutics. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030703"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e13430","DOI":"10.1111\/obr.13430","article-title":"BACE1: More than Just a \u03b2-Secretase","volume":"23","author":"Taylor","year":"2022","journal-title":"Obes. Rev. Off. J. Int. Assoc. Study Obes."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/13543776.2021.1832463","article-title":"Small-Molecule BACE1 Inhibitors: A Patent Literature Review (2011 to 2020)","volume":"31","author":"Rombouts","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.biopsych.2020.02.001","article-title":"The \u03b2-Secretase BACE1 in Alzheimer\u2019s Disease","volume":"89","author":"Hampel","year":"2021","journal-title":"Biol. Psychiatry"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/bcp.12621","article-title":"Emerging Drug Targets for A\u03b2 and Tau in Alzheimer\u2019s Disease: A Systematic Review","volume":"80","author":"West","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2050312115598250","DOI":"10.1177\/2050312115598250","article-title":"A Systematic Review and Meta-Analysis of Plasma Amyloid 1-42 and Tau as Biomarkers for Alzheimer\u2019s Disease","volume":"3","author":"Shanthi","year":"2015","journal-title":"SAGE Open Med."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Silvestro, S., Valeri, A., and Mazzon, E. (2022). Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23042011"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The Antibody Aducanumab Reduces A\u03b2 Plaques in Alzheimer\u2019s Disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e047259","DOI":"10.1002\/alz.047259","article-title":"Emerge and Engage Topline Results: Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease","volume":"16","author":"Haeberlein","year":"2020","journal-title":"Alzheimers Dement."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/alz.12286","article-title":"ENGAGE and EMERGE: Truth and Consequences?","volume":"17","author":"Kuller","year":"2021","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"key":"ref_172","unstructured":"(2022, May 26). Failure to Demonstrate Efficacy of Aducanumab: An Analysis of the EMERGE and ENGAGE Trials as Reported by Biogen, December 2019\u2014PubMed, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/33135381\/."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13195-021-00838-z","article-title":"Aducanumab Produced a Clinically Meaningful Benefit in Association with Amyloid Lowering","volume":"13","author":"Cummings","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"ref_175","unstructured":"(2022, July 02). Open Peer Commentary to \u201cFailure to Demonstrate Efficacy of Aducanumab: An Analysis of the EMERGE and ENGAGE Trials as Reported by Biogen December 2019\u201d\u2014Sabbagh\u20142021\u2014Alzheimer\u2019s & Dementia\u2014Wiley Online Library. Available online: https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/full\/10.1002\/alz.12235."},{"key":"ref_176","first-page":"193","article-title":"Aducanumab Trials EMERGE But Don\u2019t ENGAGE","volume":"9","author":"Schneider","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/d41586-021-03410-9","article-title":"More Alzheimer\u2019s Drugs Head for FDA Review: What Scientists Are Watching","volume":"599","author":"Mullard","year":"2021","journal-title":"Nature"},{"key":"ref_178","unstructured":"(2022, July 02). Controversy and Progress in Alzheimer\u2019s Disease\u2014FDA Approval of Aducanumab | NEJM. Available online: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMp2111320."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"(2022, July 02). What FDA\u2019s Controversial Accelerated Approval of Aducanumab Means for Other Neurology Drugs. Neurology Today, Available online: https:\/\/journals.lww.com\/neurotodayonline\/fulltext\/2021\/08050\/what_fda_s_controversial_accelerated_approval_of.1.aspx.","DOI":"10.1097\/01.NT.0000772736.47732.8a"},{"key":"ref_180","first-page":"22","article-title":"Controversial Approval of New Drug to Treat Alzheimer\u2019s Disease","volume":"121","author":"Aschenbrenner","year":"2021","journal-title":"Am. J. Nurs."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2021.11558","article-title":"Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered","volume":"326","author":"Rubin","year":"2021","journal-title":"JAMA"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1056\/NEJMp2110468","article-title":"Revisiting FDA Approval of Aducanumab","volume":"385","author":"Alexander","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/d41586-021-01546-2","article-title":"Landmark Alzheimer\u2019s Drug Approval Confounds Research Community","volume":"594","author":"Mullard","year":"2021","journal-title":"Nature"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41582-021-00540-6","article-title":"The Approval of Aduhelm Risks Eroding Public Trust in Alzheimer Research and the FDA","volume":"17","author":"Karlawish","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41582-020-00454-9","article-title":"Aducanumab and the FDA\u2014Where Are We Now?","volume":"17","author":"Fillit","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1177\/10600280211050405","article-title":"Accelerated Approval of Aducanumab: Where Do We Stand Now?","volume":"56","year":"2022","journal-title":"Ann. Pharmacother."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41582-021-00557-x","article-title":"Can We Learn Lessons from the FDA\u2019s Approval of Aducanumab?","volume":"17","author":"Liu","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"105754","DOI":"10.1016\/j.phrs.2021.105754","article-title":"Aducanumab for Alzheimer\u2019s Disease: A Regulatory Perspective","volume":"171","author":"Borg","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1111\/j.1742-4658.2009.06992.x","article-title":"Regulation of Secretases by All-Trans-Retinoic Acid","volume":"276","author":"Koryakina","year":"2009","journal-title":"FEBS J."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1586\/14737175.2015.1008456","article-title":"Retinoic Acid as a Therapeutic Option in Alzheimer\u2019s Disease: A Focus on Cholinergic Restoration","volume":"15","author":"Szutowicz","year":"2015","journal-title":"Expert Rev. Neurother."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1586\/ern.09.86","article-title":"All-Trans Retinoic Acid as a Novel Therapeutic Strategy for Alzheimer\u2019s Disease","volume":"9","author":"Lee","year":"2009","journal-title":"Expert Rev. Neurother."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.pbb.2014.02.016","article-title":"Retinoids as Potential Targets for Alzheimer\u2019s Disease","volume":"120","author":"Sodhi","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"e63026","DOI":"10.7554\/eLife.63026","article-title":"All-Trans Retinoic Acid Induces Synaptic Plasticity in Human Cortical Neurons","volume":"10","author":"Lenz","year":"2021","journal-title":"eLife"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1369\/0022155416679638","article-title":"All- Trans-Retinoic Acid Augments the Histopathological Outcome of Neuroinflammation and Neurodegeneration in Lupus-Prone MRL\/Lpr Mice","volume":"65","author":"Theus","year":"2017","journal-title":"J. Histochem. Cytochem. Off. J. Histochem. Soc."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1021\/cn400039s","article-title":"Retinoic Acid-Elicited RAR\u03b1\/RXR\u03b1 Signaling Attenuates A\u03b2 Production by Directly Inhibiting \u03b3-Secretase-Mediated Cleavage of Amyloid Precursor Protein","volume":"4","author":"Kapoor","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"ref_196","first-page":"157","article-title":"ERK1\/2 Is an Endogenous Negative Regulator of the Gamma-Secretase Activity","volume":"20","author":"Kim","year":"2006","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Khezri, M.R., Yousefi, K., Esmaeili, A., and Ghasemnejad-Berenji, M. (2022). The Role of ERK1\/2 Pathway in the Pathophysiology of Alzheimer\u2019s Disease: An Overview and Update on New Developments. Cell. Mol. Neurobiol.","DOI":"10.1007\/s10571-022-01191-x"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1208\/s12248-022-00683-4","article-title":"An Investigation of Instability in Dried Blood Spot Samples for Pharmacokinetic Sampling in Phase 3 Trials of Verubecestat","volume":"24","author":"Anderson","year":"2022","journal-title":"AAPS J."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1208\/s12248-022-00682-5","article-title":"A Model-Based Approach to Bridging Plasma and Dried Blood Spot Concentration Data for Phase 3 Verubecestat Trials","volume":"24","author":"Dockendorf","year":"2022","journal-title":"AAPS J."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"846459","DOI":"10.3389\/fncel.2022.846459","article-title":"Alpha- and Gamma-Tocopherol Modulates the Amyloidogenic Pathway of Amyloid Precursor Protein in an in Vitro Model of Alzheimer\u2019s Disease: A Transcriptional Study","volume":"16","author":"Shukri","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Gugliandolo, A., Chiricosta, L., Silvestro, S., Bramanti, P., and Mazzon, E. (2019). \u03b1-Tocopherol Modulates Non-Amyloidogenic Pathway and Autophagy in an In Vitro Model of Alzheimer\u2019s Disease: A Transcriptional Study. Brain Sci., 9.","DOI":"10.3390\/brainsci9080196"},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Grimm, M.O.W., Mett, J., and Hartmann, T. (2016). The Impact of Vitamin E and Other Fat-Soluble Vitamins on Alzheimer\u2019s Disease. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17111785"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"33400","DOI":"10.1074\/jbc.M109.054056","article-title":"Depletion of Vitamin E Increases Amyloid Beta Accumulation by Decreasing Its Clearances from Brain and Blood in a Mouse Model of Alzheimer Disease","volume":"284","author":"Nishida","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Lloret, A., Esteve, D., Monllor, P., Cervera-Ferri, A., and Lloret, A. (2019). The Effectiveness of Vitamin E Treatment in Alzheimer\u2019s Disease. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20040879"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2147\/CIA.S186760","article-title":"Vitamin E and Alzheimer\u2019s Disease: What Do We Know so Far?","volume":"14","author":"Browne","year":"2019","journal-title":"Clin. Interv. Aging"},{"key":"ref_206","first-page":"CD002854","article-title":"Vitamin E for Alzheimer\u2019s Dementia and Mild Cognitive Impairment","volume":"2017","author":"Farina","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2013.282834","article-title":"Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease: The TEAM-AD VA Cooperative Randomized Trial","volume":"311","author":"Dysken","year":"2014","journal-title":"JAMA"},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Yiannopoulou, K.G., Anastasiou, A.I., Zachariou, V., and Pelidou, S.-H. (2019). Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research. Biomedicines, 7.","DOI":"10.20944\/preprints201909.0270.v1"},{"key":"ref_209","first-page":"1135","article-title":"Alzheimer\u2019s Disease: Many Failed Trials, so Where Do We Go from Here?","volume":"68","author":"Reiss","year":"2020","journal-title":"J. Investig. Med. Off. Publ. Am. Fed. Clin. Res."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/jgs.15830","article-title":"Major Clinical Trials Failed the Amyloid Hypothesis of Alzheimer\u2019s Disease","volume":"67","author":"Huang","year":"2019","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_211","unstructured":"(2022, May 26). Alzheimer\u2019s Disease: Key Insights from Two Decades of Clinical Trial Failures\u2014PubMed, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/35342092\/."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"e2129392","DOI":"10.1001\/jamanetworkopen.2021.29392","article-title":"Evaluation of the Cost-Effectiveness of Drug Treatment for Alzheimer Disease in a Simulation Model That Includes Caregiver and Societal Factors","volume":"4","author":"Ito","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.3233\/JAD-132639","article-title":"Effectiveness and Cost-Effectiveness of the Pharmacological Treatment of Alzheimer\u2019s Disease and Vascular Dementia","volume":"42","author":"Versijpt","year":"2014","journal-title":"J. Alzheimers Dis. JAD"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1463-1326.2010.01337.x","article-title":"The Effect of Pramlintide Acetate on Glycemic Control and Weight in Patients with Type 2 Diabetes Mellitus and in Obese Patients without Diabetes: A Systematic Review and Meta-Analysis","volume":"13","author":"Perez","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Merlo, S., Spampinato, S.F., and Lim, D. (2021). Molecular Aspects of Cellular Dysfunction in Alzheimer\u2019s Disease: The Need for a Holistic View of the Early Pathogenesis. Biomolecules, 11.","DOI":"10.3390\/biom11121807"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/7\/996\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:52:28Z","timestamp":1760140348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/7\/996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,17]]},"references-count":215,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["biom12070996"],"URL":"https:\/\/doi.org\/10.3390\/biom12070996","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,17]]}}}